The use of nuclear medicine in paediatrics has experienced a rapid and continuous development over the past 15 years, despite the introduction of computed tomography, echography, and magnetic resonance.
Nuclear medicine is based on the principle that a radioisotope is an unstable substance that gives off energy at a particular level as it decays into a stable compound. The ability to 'label' certain radioisotopes allows a minute quantity of this isotope to be specifically directed at one cell type or organ so that functional images result.
This specific uptake may compensate the lack of resolution compared with other imaging techniques. For instance, the selective uptake of technetium 99mTc labelled dimercaptosuccinic acid (DMSA) by the tubular cells allows the recognition of focal areas of pyelonephritis, which can be missed by ultrasound or intravenous urography. Iodine 123 (1231) labelled metaiodobenzylguanidine (MIBG) is selectively taken up by the chromaffin tissue, allowing the detection of neuroblastoma metastases, which are not seen by other techniques. Beside the morphological aspects the selective uptake or excretion, or both, of a tracer by an organ makes it possible to quantify one or more functions related to this organ. Nuclear medicine procedures are safe, minimally invasive, and generally expose the child to a very low radiation dose.
Patient preparation
Most radioisotope examinations do not require any patient preparation. In dynamic renal scintigraphy a well hydrated child is not only a happy cooperative child but hydration also permits optimum analysis of the renal scan. When searching for the presence of ectopic gastric mucosa the child must have nothing orally for 4 hours before the examination.
Sedation is rarely used in most paediatric institutions and also in those adult centres geared to carry out a considerable number of studies in children.
The general principle that radiation has to be kept at the lowest possible level has meant that those isotopes commonly used have a short half life (for example, 99mTc=6 hours or 1231=13*3 hours) and Radioactive tracers The general principle that radiation has to be kept at the lowest possible level has meant that those isotopes commonly used have a short half life (for example, 99mTc=6 hours or 1231 =13-3 hours) and emit gamma rays at an appropriate level for a gamma camera. The ability to label 99mTc with various different specific non-toxic chemicals has allowed most examinations requiring nuclear medicine in paediatrics to concentrate on investigating various aspects of renal function, pulmonary perfusion, and disorders of the skeleton as well as the reticuloendothelial system. In addition, imaging of the gut and thyroid gland as well as congenital heart disease have all benefited from the use of 99mTc. Labelling of white blood cells with a 99mTc complex is also now available.
Radiation
'As compared to ionizing radiation used externally in diagnostic radiology, the use of radiopharmaceuticals results in internally absorbed doses delivered at much lower dose-rates, which generally are considered to have less biological effect.' This quotation is from the radiation protection body of the United States (National Council on Radiation Protection and Measurements. N°73,1983 ) and should encourage the use of nuclear medicine in paediatrics.
Low irradiation, no sedation of the patient, and absence of appreciable side effects characterise the radionuclide techniques, which provide useful morphological and functional information and are particularly well adapted to the paediatric patient. 
Indications19
(1) Jaundice to exclude biliary atresia in the infant; to assess postsurgical patency of biliary tree; to assess drainage in choledocal cyst and the presence of dilated ducts-for example, Caroli's disease. There are protagonists of each isotope and in the investigation of a thyroid nodule it may be unimportant which tracer is used.
HEART DISEASES (TABLE 7) Indications'7 [29] [30] [31] (1) Assessment of left to right heart shunt using 99MTc pertechnetate.
(2) Assessment of right to left heart shunt using 99mTc macroaggregates (MAA). Pertechnetate-technetium 99m This isotope will be taken via the right heart to the lungs then to the left heart and on to the systemic circulation. In the presence of a left to right shunt isotope will go from the left heart phase both to the systemic circulation and also back to the lungs. The shunt can be quantified.
Macroaggregates-technetium 99m
The isotope will be trapped in the first capillary plexus and thereforc after an intravenous injection all the isotope is normally stopped in the pulmonary capillary bed. In the presence of a right to left shunt the isotope is seen in the tystemic circulation-for example, kidneys. Red blood cells-technetium 99m
As the isotope is attached to the red blood cell mass images of the pulsating heart can be obtained over a period of time in order that ventricular function can be assessed.
Changes in function can be measured (ejection fraction).
Krypton gas-181 m This isotope will come out of solution as soon as it is in contact with air. If the "lmKr is given by constant intravenous infusion then the isotope will enter the right heart and then the pulmonary circulation. The isotope will freely cross the alveolar membrane and be exhaled so that no isotope will reach the pulmonary veins or left heart normally. Good delineation of the right ventricular structures can therefore be reached, without any superposition of the left heart; this allows a measurement of the right ventricular contractility. 
